As Treg express CCR5, a current phase1/2 clinical trial investigates the therapeutic efficacy of CCR2 and CCR5 inhibitors in advanced PDAC with the aim to reduce Treg, MDSC and M2-polarized TAM and to increase anti-tumor immunity [209]. This evidence concerns the gene CCR5 and neoplasm.